Angela S. Lalor
Known title: DirectorCIK: 0001348355
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Danaher Expands AI Integration in Scientific Research. Danaher has announced a partnership to integrate AI into scientific research workflows, a move that could enhance its diagnostic and drug discovery capabilities. With Q3 earnings approaching, investors are watching to see if this strategic shift supports the company's recovery narrative. The stock currently trades near its 52-week high, reflecting optimism about these operational improvements.
Transaction History
| ENOV | ▲ Buy | Grant | 9,346 | $0 | 5/19/2026 | View on chart |
| ENOV | ▲ Buy | Grant | 845 | $0 | 12/31/2025 | View on chart |
| ENOV | ▲ Buy | Grant | 742 | $0 | 9/30/2025 | View on chart |
| ENOV | ▲ Buy | Grant | 718 | $0 | 6/30/2025 | View on chart |
| ENOV | ▲ Buy | Grant | 6,598 | $0 | 5/21/2025 | View on chart |
| ENOV | ▲ Buy | Grant | 589 | $0 | 3/31/2025 | View on chart |
| ENOV | ▲ Buy | Grant | 513 | $0 | 12/31/2024 | View on chart |
| ENOV | ▲ Buy | Grant | 523 | $0 | 9/30/2024 | View on chart |
| ENOV | ▲ Buy | Grant | 498 | $0 | 6/28/2024 | View on chart |
| ENOV | ▲ Buy | Grant | 4,338 | $0 | 5/20/2024 | View on chart |
| ENOV | ▲ Buy | Grant | 361 | $0 | 3/28/2024 | View on chart |
| ENOV | ▲ Buy | Grant | 402 | $0 | 12/29/2023 | View on chart |
| ENOV | ▲ Buy | Grant | 427 | $0 | 9/29/2023 | View on chart |
| ENOV | ▲ Buy | Grant | 313 | $0 | 6/30/2023 | View on chart |
| ENOV | ▲ Buy | Grant | 1,875 | $0 | 5/16/2023 | View on chart |
| ENOV | ▲ Buy | Grant | 328 | $0 | 3/31/2023 | View on chart |
| ENOV | ▲ Buy | Grant | 327 | $0 | 12/30/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 380 | $0 | 9/30/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 319 | $0 | 6/30/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 1,648 | $0 | 6/7/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 396 | $0 | 6/7/2022 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 1,627 | $442K | 2/24/2022 | View on chart |
| DHR | ▲ Buy | Grant | 22,770 | $0 | 2/23/2022 | View on chart |
| DHR | ▼ Sell | Tax Withholding | 4,118 | $1.2M | 2/1/2022 | View on chart |
| DHR | ▲ Buy | Option Exercise | 37,513 | $2.5M | 11/29/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 37,513 | $12.3M | 11/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Enovis joins AAOS Registry Program as industry sponsor
Enovis has become the first multi-registry industry sponsor of the AAOS Registry Program. This move highlights the company's engagement with major orthopedic data initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $38.33.
Enovis joins AAOS Registry Program as industry sponsor. Enovis has become the first multi-registry industry sponsor of the AAOS Registry Program. This move highlights the company's engagement with major orthopedic data initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $38.33.